Source: PubMed
Balance and gait improved in patients with MS after physiotherapy based on the Bobath concept.
Smedal T, Lygren H, Myhr KM, Moe-Nilssen R, Gjelsvik B, Gjelsvik O, Inger L.
National Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway. tori.smedal@helse-bergen.no
Physiother Res Int. 2006 Jun;11(2):104-16
BACKGROUND AND PURPOSE: Patients with multiple
sclerosis (MS) tend to have movement difficulties, and the effect of
physiotherapy for this group of patients has been subjected to limited
systematic research. In the present study physiotherapy based on the Bobath
concept, applied to MS patients with balance and gait problems, was evaluated.
The ability of different functional tests to demonstrate change was evaluated.
METHOD: A single-subject experimental study design with ABAA phases was used,
and two patients with relapsing-remitting MS in stable phase were treated. Tests
were performed 12 times, three at each phase: A (at baseline); B (during
treatment); A (immediately after treatment); and A (after two months). The key
feature of treatment was facilitation of postural activity and selective control
of movement. Several performance and self report measures and interviews were
used. RESULTS: After intervention, improved balance was shown by the Berg
Balance Scale (BBS) in both patients, and improved quality of gait was indicated
by the Rivermead Visual Gait Assessment (RVGA). The patients also reported
improved balance and gait function in the interviews and scored their condition
as 'much improved'. Gait parameters, recorded by an electronic walkway, changed,
but differently in the two patients. Among the physical performance tests the
BBS and the RVGA demonstrated the highest change, while no or minimal change was
demonstrated by the Rivermead Mobility Index (RMI) and Ratings of Perceived
Exertion (RPE). CONCLUSION: The findings indicate that balance and gait can be
improved after physiotherapy based on the Bobath concept, but this should be
further evaluated in larger controlled trials of patients with MS.
PMID: 16808091 [PubMed - in process]